NexImmune, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| NexImmune, Inc. | NEXI - NASDAQ |
$15.00-$17.00 | $17.00 | $23.01 | 6.5 million | 2/12/2021 |
| Barclays, Cantor, Raymond James, Allen & Co. | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-01-19 Terms Added 2021-02-08 Terms Added 2021-02-08 Amended Terms 2021-02-11 | ||||||
NexImmune, Inc. Quote & Chart - Click for current quote - NEXI
IPO Boutique aggregates information on public companies and private companies, such as "NEXI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About NexImmune, Inc. (adapted from NexImmune, Inc. prospectus):
They are a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "NEXI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.